I Did Mushrooms for Science, Pt. 1

Johnson calculates the total psychoactive alkaloid dose and observes that whole mushroom weight may be more predictive than isolated psilocybin content because other alkaloids likely play a synergistic role, 'combinatorially explosive' at the neurochemical level. He is approaching this as a longitudinal experiment, not a recreational trip: the dose is intended to push the system enough to see measurable biological change. He also notes that genetic predisposition, environment, pre-existing health, and mental state all influence outcome, and he jokes about people guessing he will be 'overwhelmed.' This is part 1, so the effects are not shown; this is the protocol as planned.

The Blueprint Advanced Panel is a proprietary blood test that covers multiple pages of biomarkers, far beyond standard blood work, reflecting Johnson's systematic biomarker optimization philosophy. By measuring before and after, he hopes to see shifts—perhaps in inflammation, epigenetic markers, or metabolic panels—that could hint at a longevity effect. He mentions also measuring cortisol and wearables, making it a multi-faceted physiological snapshot. This protocol is part of his larger Blueprint endeavor to quantify all biological interventions.

This protocol is unprecedented in self-experimentation because typical brain measurement during a strong psychedelic trip requires an fMRI bay, which is impractical and confining. Johnson's Kernel Flow allows him to walk around or lie down in a natural setting while still capturing brain data. He emphasizes that this is the first time Kernel Flow is being used in this context, making it a milestone for both his company and psychedelic neuroscience. The data will be analyzed to see how brain networks reorganize acutely and whether there are lingering changes days later.

This is part of Johnson's broader philosophy that subjective experiences should be paired with objective physiological markers. While many focus on the psychological content of a trip, he wants to see whether the body's stress response shows a measurable spike, and if so, how it correlates with subjective intensity or later biomarker changes. The wearable data could also indicate whether there are periods of deep rest or autonomic reset during the trip, hinting at a restorative mechanism.

Johnson describes this as a 'wide net' experiment after encountering recent studies showing interesting effects in both mice and human cells. He is not starting with a specific hypothesis about mechanism; rather, he is measuring a huge array of biomarkers to see if any signal of rejuvenation or longevity emerges. He openly acknowledges the limitation: 'psychedelics fix broken things. Psychedelics don't make things younger.' Yet he believes that society reframing psychedelics under a longevity lens could be a big deal because it changes the conversation from mental illness to biological aging. The experiment is a high-risk personal endeavor to generate data where none publicly exists.

He describes Kernel Flow as 'like a pulse oximeter for the brain' and 'a wearable for the brain,' comparing it to a bike helmet. He has been wearing it daily for a week leading up to the trip to establish a baseline. At the peak of the mushroom experience, he will capture brain activity, then continue daily after. This dataset, combined with blood biomarkers and wearables, could provide unprecedented insight into the neural correlates of a high-dose psychedelic experience and any lasting changes. He mentions that measuring your brain is 'really challenging,' which motivated the 7-year development, making this a showcase of the technology.

The biomarker battery includes a 'Blueprint Advanced Panel, six pages' of blood markers drawn before and after the trip, plus salivary cortisol, continuous wearable data (likely heart rate variability, temperature, etc.), and the Kernel brain data. He explicitly notes the blood draw is 'a big one' and that they will monitor vascular markers on Friday to detect any physiological shift. This approach aligns with his philosophy of generating hard biological data where subjective reports dominate. He is not advocating for others to replicate this; it's a personal, high-investment inquiry into whether a psychedelic can shift aging biomarkers.